Seismic Therapeutic’s Post

🦈 Dive into the world of #Nanobodies with our new product: #Shark #PBMCIsolation Kit! Effortlessly isolate highly purified #PeripheralBloodMononuclearCells (#PBMCs) from 100 mL of shark whole blood, unlocking the potential for discovering novel nanobodies. 🌟 Accelerate your research in antibody engineering, diagnostics, and therapeutics. 🚀 Visit jotbody.com to learn more and embark on a journey of nanobody discovery with our game-changing kit! #ScientificBreakthrough #NanobodyResearch #AntibodyEngineering

🌟 iBio, Inc. is proud to attend the Antibody Engineering & Therapeutics Conference in our hometown of San Diego this week! 🌟 Our leaders, Kristi Sarno, SVP of Business Development, and Cory Schwartz, Director of Drug Discovery, are on the ground representing iBio’s cutting-edge advancements in AI-driven antibody discovery and development. This event is pivotal for showcasing how iBio's Machine Learning Antibody Discovery Engine and technologies like Epitope Steering, ShieldTx™, and EngageTx™ are accelerating the creation of first-in-class and best-in-class therapeutics. By addressing hard-to-drug targets and reducing preclinical timelines, we're shaping the future of cardio-metabolic therapeutics and immuno-oncology drugs. As San Diego continues to thrive as a biotech hub, our presence reflects iBio's commitment to innovation and collaboration within this vibrant #biotech ecosystem. Conferences like these are where strategic partnerships form, groundbreaking ideas emerge, and the future of antibody engineering takes shape. 💡 Let’s connect! If you’re at the conference, we’d love to discuss how #iBio can support your pipeline goals or explore partnership opportunities. #AntibodyEngineering #MachineLearning #ImmunoOncology #SanDiegoBiotech #Collaboration #iBio

Today is the last day of Antibody Engineering & Therapeutics in San Diego! Check out our poster, “Robust and Streamlined Approach for High-Throughput Sequencing of OmniRat Antibody Repertoires.” See our team in booth 300 to continue the conversation! #AntibodyEng

"Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with #PDIinhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data," said Panna Sharma, CEO and President of Lantern Pharma. "Our #AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That's where RADR® can play a highly essential and market defining role." https://lnkd.in/gabi_27S #biotech #businessdevelopment #artificialintelligence

Now, we’re going live! I’m thrilled to connect with industry leaders at PODD in Boston on October 28-29, where we’ll unveil our novel and revolutionary drug delivery platform - featuring customizable nanoporous silicon dioxide (nPSi) particles tailored to customer-specific applications and release profiles. This next-generation technology surpasses traditional mesoporous silica-based and lipid nanoparticle (LNP) systems, offering superior stability, extended payload capacity, and enhanced durability. Our platform is designed to transform targeted delivery in e.g. oncology and RNA-based therapies, while providing cutting-edge solutions for extended-release applications, including contraceptives, AMD treatments, and immunology. With our smart sealing and tailored release technology, we can extend the release and durability of therapies for months. 💡 Disruptive innovation is here! Visit us at Booth 106 to learn more! 👉 www.sicarebio.com (live on October 28th) #sicarebio #drugdelivery #targetedelivery #extendedrelease #trutags #RNA #genetherapy #oncology #AMD #vaccines #glp1 #insulin #chemotherapy

The Swiss Biotech Day event has just ended. I wanted to share some thoughts after very interesting conversations and talks. 🖥️ It's simply amazing to see AI revolutionising the pharma and biotech industries, from drug development to clinical trial optimisation. 🧬 Biologics, such as ADCs, nanoparticles (such as exosomes and viral vectors) and cell therapies are sparking conversations for their role, especially in cancer treatments. The potential is thrilling! 🤶 Rejuvenation is marking a new frontier for therapeutic innovation. 💊 The impact of Annex 1 is undeniable, leading to major restructuring for some CDMOs to stay ahead. 💡 Start-up pitches? Pure dynamism and creativity! 💰 Finally, witnessing the strategic investments flowing into Switzerland was a highlight. Multicultural, innovative, government support are the main drivers for investors to look into Swiss companies. #SwissBiotechDay #BiotechInnovation #InvestmentTrends #GlobalBiotech

"Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with #PDIinhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data," said Panna Sharma, CEO and President of Lantern Pharma. "Our #AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That's where RADR® can play a highly essential and market defining role." https://lnkd.in/gabi_27S #biotech #businessdevelopment #artificialintelligence

Today, Schrödinger team members presented new preclinical data on SGR-3515, our investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that leads to deeper and more durable responses compared to inhibitors that target only Wee1 or Myt1. Schrödinger will also present preclinical data from our PRMT5-MTA program during a poster session on October 25. Learn more about both presentations in our press release: https://hubs.li/Q02VsG9F0

Accelerate your antibody discovery process with the AbNano™ VHH Naïve Library from Abcore | Fortis Life Sciences 🦙 The AbNano™ VHH Naïve Library is a fully natural, single domain naïve library derived from camelid source material and the antibodies displayed on monovalent phage. It is intended for research purposes to aid in the discovery of antibodies intended for use as therapeutics, diagnostics, and research tools. Learn more at https://ow.ly/VYhG50QQI7K

⬆️💰#Therapeutic #antibodymanufacturing requires expensive and complex production that keeps treatment costs high. ⬇️💰Encoding antibodies with #mRNA has the potential to circumvent many traditional antibody manufacturing challenges, significantly reducing cost and time to clinic. 📊With new data illustrating preclinical feasibility, the approach has recently matured to a viable therapeutic option. ➡️Register for our live webinar on 12/12 to learn about this #newfrontier in #antibodyproduction and get your questions answered by Charles River Laboratories Roxana Redis, Dan Rocca, and Vernal Biosciences Sourav Mukherjee, PhD. https://lnkd.in/gg3PWtq5